WO2002036768A1 - Cell division autoantigen (cda) polypeptides, gene sequences and uses thereof - Google Patents
Cell division autoantigen (cda) polypeptides, gene sequences and uses thereof Download PDFInfo
- Publication number
- WO2002036768A1 WO2002036768A1 PCT/AU2001/001418 AU0101418W WO0236768A1 WO 2002036768 A1 WO2002036768 A1 WO 2002036768A1 AU 0101418 W AU0101418 W AU 0101418W WO 0236768 A1 WO0236768 A1 WO 0236768A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cda
- polypeptide
- fragment
- mutant
- analogue
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 116
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 114
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 112
- 230000032823 cell division Effects 0.000 title claims abstract description 38
- 108090000623 proteins and genes Proteins 0.000 title abstract description 63
- 239000012634 fragment Substances 0.000 claims abstract description 78
- 239000002773 nucleotide Substances 0.000 claims abstract description 47
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 47
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 22
- 201000011510 cancer Diseases 0.000 claims abstract description 22
- 239000013598 vector Substances 0.000 claims abstract description 16
- 229960005486 vaccine Drugs 0.000 claims abstract description 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 6
- 210000004027 cell Anatomy 0.000 claims description 157
- 238000000034 method Methods 0.000 claims description 60
- 230000000694 effects Effects 0.000 claims description 33
- 230000014509 gene expression Effects 0.000 claims description 29
- 150000001413 amino acids Chemical class 0.000 claims description 26
- 230000010261 cell growth Effects 0.000 claims description 19
- 230000008859 change Effects 0.000 claims description 16
- 230000001965 increasing effect Effects 0.000 claims description 15
- 230000026731 phosphorylation Effects 0.000 claims description 15
- 238000006366 phosphorylation reaction Methods 0.000 claims description 15
- 239000005557 antagonist Substances 0.000 claims description 14
- 230000022131 cell cycle Effects 0.000 claims description 14
- 239000013604 expression vector Substances 0.000 claims description 11
- 108091000080 Phosphotransferase Proteins 0.000 claims description 10
- 102000020233 phosphotransferase Human genes 0.000 claims description 10
- 239000013599 cloning vector Substances 0.000 claims description 9
- 239000013612 plasmid Substances 0.000 claims description 9
- 101150012716 CDK1 gene Proteins 0.000 claims description 7
- 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 claims description 7
- 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 claims description 7
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims description 7
- 230000008685 targeting Effects 0.000 claims description 7
- 108020004705 Codon Proteins 0.000 claims description 5
- 241000700605 Viruses Species 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 241001515965 unidentified phage Species 0.000 claims description 4
- 241000282552 Chlorocebus aethiops Species 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 238000013518 transcription Methods 0.000 claims description 3
- 230000035897 transcription Effects 0.000 claims description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 2
- 241000238631 Hexapoda Species 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 241000607142 Salmonella Species 0.000 claims description 2
- 230000027455 binding Effects 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 244000005700 microbiome Species 0.000 claims description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 7
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 231100000433 cytotoxic Toxicity 0.000 abstract description 5
- 230000001472 cytotoxic effect Effects 0.000 abstract description 5
- 238000011282 treatment Methods 0.000 abstract description 5
- 230000002163 immunogen Effects 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 abstract description 3
- 239000000032 diagnostic agent Substances 0.000 abstract description 2
- 229940039227 diagnostic agent Drugs 0.000 abstract description 2
- 229940124597 therapeutic agent Drugs 0.000 abstract description 2
- 102000004169 proteins and genes Human genes 0.000 description 54
- 108020004414 DNA Proteins 0.000 description 41
- MZZYGYNZAOVRTG-UHFFFAOYSA-N 2-hydroxy-n-(1h-1,2,4-triazol-5-yl)benzamide Chemical compound OC1=CC=CC=C1C(=O)NC1=NC=NN1 MZZYGYNZAOVRTG-UHFFFAOYSA-N 0.000 description 18
- 101000658622 Homo sapiens Testis-specific Y-encoded-like protein 2 Proteins 0.000 description 18
- 102100034917 Testis-specific Y-encoded-like protein 2 Human genes 0.000 description 18
- 108700019146 Transgenes Proteins 0.000 description 16
- 108020001507 fusion proteins Proteins 0.000 description 15
- 102000037865 fusion proteins Human genes 0.000 description 15
- 239000002299 complementary DNA Substances 0.000 description 12
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 10
- 230000018199 S phase Effects 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 230000001363 autoimmune Effects 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 230000002194 synthesizing effect Effects 0.000 description 8
- 239000000427 antigen Substances 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 210000001550 testis Anatomy 0.000 description 7
- 239000000523 sample Substances 0.000 description 6
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 238000010348 incorporation Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 4
- 229960003722 doxycycline Drugs 0.000 description 4
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000003119 immunoblot Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108091036407 Polyadenylation Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 102000005936 beta-Galactosidase Human genes 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 101710173353 Cytotoxicity-associated immunodominant antigen Proteins 0.000 description 2
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000007999 Nuclear Proteins Human genes 0.000 description 2
- 108010089610 Nuclear Proteins Proteins 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 102100027171 Protein SET Human genes 0.000 description 2
- 101710148582 Protein SET Proteins 0.000 description 2
- 102220499960 Testis-specific Y-encoded-like protein 2_S20A_mutation Human genes 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 210000005221 acidic domain Anatomy 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000004900 c-terminal fragment Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- JBIWCJUYHHGXTC-AKNGSSGZSA-N doxycycline Chemical compound O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O JBIWCJUYHHGXTC-AKNGSSGZSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229940021993 prophylactic vaccine Drugs 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229940021747 therapeutic vaccine Drugs 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 230000004668 G2/M phase Effects 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101000693916 Gallus gallus Albumin Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 101000836351 Homo sapiens Protein SET Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000143 anti-replicative effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 238000002701 cell growth assay Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012539 chromatography resin Substances 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000057013 human SET Human genes 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000012622 synthetic inhibitor Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 231100000164 trypan blue assay Toxicity 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the present invention relates to a Cell Division Autoantigen (CDA) and includes polypeptide sequences, gene sequences encoding CDA, vectors containing those sequences, and host cells transformed to contain CDA sequences.
- CDA Cell Division Autoantigen
- the invention also provides antibodies directed against CDA.
- the invention also relates to the use of CDA as a therapeutic and diagnostic agent for the treatment of cell division associated diseases including cancer.
- INTRODUCTION Cancer is a general term given to a range of diseases, all of which are the result of the uncontrolled division of cells. There are a range of useful chemical entities available to clinicians for the treatment of cancer. Such agents include antimetabolites, DNA binding compounds, alkylating agents and hormones. These substances are usually cytotoxic and therefore also adversely affect normal cells.
- An alternative approach to arresting uncontrolled cell division in a mammal is to identify naturally occurring proteins which act specifically to regulate the cell cycle. It is known that the cell cycle is a strictly regulated and complicated chain of events involving many regulatory proteins and pathways. Enormous information exchanges between those proteins and pathways act to maintain a balance between normal and uncontrolled cell growth. Identification of proteins which can act to arrest the growth of S phase cells by preventing the synthesis of the DNA necessary for cell division to occur could lead to use of the protein in cancer therapy. Polypeptides which are part of cell cycle regulatory pathways may be found in the nucleus of rapidly growing cells.
- a nucleotide sequence encoding a cell division autoantigen (CDA) said sequence having the nucleotide sequence according to Figure 1 or SEQ ID NO:1 or a fragment, functional equivalent , analogue, mutant or variant thereof.
- CDA cell division autoantigen
- nucleotide sequence which encodes a CDA polypeptide or CDA-derived polypeptide fragment, functional equivalent, analogue, mutant or variant thereof said polypeptide having a sequence according to Figure 1 or SEQ ID NO:2.
- the cell division autoantigen has been found by the applicants to be a nuclear protein that resides primarily in the nucleolus and to a lesser extent in the nucleoplasm of the cell.
- the function of the protein has been linked to cell division because of its homology to portion of the Leukaemia-associated protein SET which is also involved in cell division control.
- the CDA has been shown by the applicants that it may halt cell growth.
- an expression vector or cloning vector encoding a cell division auto-antigen (CDA) said vector including the nucleotide sequence according to Figure 1 or SEQ ID NO:1 , or a fragment, functional equivalent, analogue, mutant or variant thereof.
- CDA cell division auto-antigen
- the present invention also provides a host cell transformed or transfected with an expression vector or cloning vector including a nucleotide sequence according to Figure 1 or SEQ ID NO:1 or a fragment, functional equivalent, analogue, mutant or variant thereof encoding a CDA polypeptide or CDA- derived polypeptide, functional equivalent, analogue, mutant, or variant thereof.
- an amino aci sequence encoding a cell division auto-antigen and having the amino acid sequence according to Figure 1 or SEQ ID NO:2 or a fragment, functional equivalent, analogue, mutant or variant thereof.
- an isolated or sustantially pure CDA polypeptide encoded by an amino acid sequence or nucleotide sequence according to Figure 1 or SEQ ID NO:2 or a fragment, functional equivalent, analogue, mutant or variant thereof.
- antibodies that specifically bind CDA polypeptide or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants, and variants thereof.
- the present invention also includes therapeutic or prophylactic vaccines and pharmaceutical compositions comprising CDA polypeptide or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants, and variants thereof, or antibodies to these polypeptides in a pharmaceutically acceptable carrier.
- a pharmaceutically acceptable carrier for example, an immunologically effective amount of the CDA polypeptide or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants, and variants thereof may be used.
- Antagonists may act to inhibit activity of the CDA polypeptide generally by blocking its action on the cells.
- the antagonist may also prevent phosphorylation which appears to be important in the activity of the CDA.
- a method of controlling cell division including subjecting cells to an effective amount of CDA or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants, and variants thereof to control cell division.
- a method of preventing and treating cancer including providing an effective amount of CDA or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants, and variants thereof to a patient in need, said amount being effective to halt or slow down cell growth.
- a method of detection of cell cycle activity including measuring the presence of CDA polypeptide or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants, and variants thereof.
- a method of increasing cell division including eliminating expression of CDA polypeptide or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants, and variants thereof.
- the present invention encompasses the CDA polypeptide and CDA-derived polypeptides and methods for making the peptides.
- the invention also encompasses antisera and antibodies, including cytotoxic antibodies specific for the CDA polypeptide and/or CDA-derived polypeptides.
- the invention further encompasses immunogenic, prophylactic or therapeutic compositions, including vaccines, comprising one or more polypeptides.
- the invention additionally encompasses nucleotide sequences encoding said CDA polypeptide or CDA-derived polypeptides, functional equivalents, analogues, mutants, and variants thereof.
- Figure 1 shows the nucleotide sequence and the amino acid sequence of CDA.
- Figure 2a and Figure 2b shows nucleic acid and predicted amino acid sequences of CDA.
- the predicted amino acids are represented by single letter codes with an in-frame stop codon (*).
- the sequence shows 4 putative nuclear targeting motifs (boxed), two putative cdc2 kinase phosphorylation sites (shaded) with the candidate phosphorylated residue in bold, and polyadenylation signal sequence (bold and italics) located 15 nucleotides upstream of poly (A) tail. Amino acids in the central and C-terminal tail which are homologous to SET are underlined.
- Figure 3 shows immunoblot and immunoreactivity of clone hT4 with the autoimmune serum ⁇ -galactosidase fusion protein with estimated molecular weight of 135 kDa (arrow) produced by lambda gt11 clone hT4 ( ⁇ gt11 hT4), is immunoreactive with the autoimmune serum, but not with the normal human serum, ⁇ -galactosidase protein (120 kDa) produced by wild type lambda gt11 ( ⁇ gt 11 WT) is not reactive with the autoimmune serum.
- Figure 4 shows the molecular and structural features of CDA.
- I stick diagram showing N-terminal proline rich (Pr) domain (aa 4 - 121), basic domain (aa 180 - 418), C-terminal acidic domain comprising two acidic regions (aa 420-536 and 564-675, respectively), 4 putative nuclear targeting motifs (aa 9-15; 187- 203; 404-407 and 411-414) and 2 cdc2 kinase phophorylation sites (Ser20 and Thr340).
- Pr proline rich
- aa 4 - 121 basic domain
- C-terminal acidic domain comprising two acidic regions
- 4 putative nuclear targeting motifs aa 9-15; 187- 203; 404-407 and 411-414
- 2 cdc2 kinase phophorylation sites Ser20 and Thr340.
- Kyte-Doolitle hydrophilicity profile showing that CDA1 is generally hydrophilic.
- FIG. 5 shows CDA is phosphorylated in vivo.
- Overexpressed myc-tagged full length (A) and N-terminal two thids (B) of CDA1 are metabolically labelled by 35 S-methionine and immunoprecipitated by anti-myc-tag McAb 9E10, and migrate in the SDS-PAGE as apparent molecular weight of 120 kDa (arrow) and 60 kDa (arrow), respectively. They both are labelled by 32 P in vivo and immuno- precipitate any 35 S, nor 32 P labelled proteins.
- Figure 6 shows Northern blots illustrating molecular size of CDA mRNA in human testis tissue and HeLa cell lines.
- RNA blots show a single 2.8 kb mRNA band of CDA in HeLa cells and human testis detected by hybridisation with CDA cDNA probes labelled with 32 P-dCTP.
- Approximately 350ng poly A+ RNA of Hela cells and human testis were hybridised respectively with probe 1 (PCR fragment from clone hT6 corresponding to nucleotides 1421 - 2280) and probe 2 and 3 (PCR fragments from clone hTsl-9 corresponding respectively to nucleotides 1595 - 2808 and 741 - 1418).
- Figure 7 shows species distribution of CDA.
- A Rabbit antiserum raised against a bacterial fusion protein of GST and CDA1 C-terminus (GST-hT4) is affinity purified by firstly removing anti-GST antibodies followed by a GST-hT4 fusion protein affinity column purification.
- Whole serum i) contains both anti-GST (lanes 1) and anti-GST-hT4 fusion protein (lanes 2) antibodies; the flow-through fraction of the first GST-column (ii) with anti-GST antibodies removed retains the anti-GST-hT4 fusion protein antibodies (iii) are reactive with GST-hT4 fusion protien, but not with the purified GST.
- the affinity purified antibodies are reactive with CDA1 of approimately 120 kDa in HeLa and HepG2 cells of human origin, as well as COS cells of monkey. No band around 120 kDa was detected by the antibodies from cell lines of dog (MDCK), mouse (thymus B6TEA and 133.D7), hamster (CHO and BHK) and chicken (SSC). Approximately 30 ⁇ g/lane total protein extract was loaded, and the blot was re- blotted with anti-alpha tubuline monoclonal antibody to show equal loading of each lane.
- Figure 8A and 8B (1 and 2) shows the effect of various levels of CDA on cell growth.
- the DOX concentrations are: 5.00ng/mL (a); O. ⁇ Ong.mL (b); 0.25ng/mL (c); 0.13ng/mL (d); 0.06ng.mL (e) and O.OOng/mL (f).
- B Approimately 2 x 10 5 cells were seeded in each dish (10cm) and cultured in presence of DOX at various concentrations as indicated for 4 days. Cells were labelled with BrdU for 1 hr and stained with anti-BrdU Ab- FITC conjugate and propidium iodide. The dot plot shows the DNA synthesizing cells content equivalent to S phase cells but are not synthesizing DNA are measured and shown (R4).
- the viability of the cells determined by Trypan blue eclusion assay is also shown (Viable).
- the histogram shows the number of cells (counts) against the DNA contents (FL2-A).
- B1 shows the results for full length CDA and B2 shows results for N-terminus CDA.
- Figure 9A and 9B show effect of CDA overexpression on cell growth.
- A Equal number of cells (4 x 10 4 ) were seeded in 6 well plates and cultured with DOX in the medium overnight. To switch the transgene on, the DOX was removed by replacing the medium and the cells were cultured for 1-5 days. Cells were fixed and stained with 0.1% crystal violet daily. The cell associated dye was then extracted in 10% acetic acid, and the OD (495nm) was measured and plotted against the days. Full length CDA cell line is represented by the faint bar, while the N-terminus cell line by the solid bar.
- B Approximately 2 x 10 5 cells were seed in each 10mm dish, and cultured without DOX to switch on the transgene for 5 days.
- the dot plot shows the DNA synthesizing cells incorporating BrdU (FL1 H) and the DNA contents (FL2-A). Percentage of the cells that have DNA content equivalent to S phase cells but are not synthesizing DNA are measured and shown (R4). The viability of the cells determined by Trypan blue exclusion assay is also shown (Viable). The histogram shows the number of cells (counts) against the DNA contents (FL2-A). B1 shows the results for full lengths CDA and B2 shows eresults for N-terminus CDA.
- Figure 10 shows the inhibitory effect of CDA on cell growth is disabled by point mutations that abolish the potential cdc2 kinase phosphorylation sites.
- Approximately 4 x 10 6 tTa HeLa cells were transient transfected with 15 ⁇ g pTRE construct containing either wild type CDA (Wt) or a double mutant (DM) CDA that has 2 point mutations (S20A and T340A).
- the transfected cells were cultured for 48 hrs in presence (D+) or absence (D-) of DOX before FACS analysis.
- the dot plots show the DNA synthesizing cells incorporating BrdU (FL1 H) and the DNA contents (FL2-A).
- the cells in region 3 (R3) are Synthesizing DNA and have BrdU incorporated.
- R2 cells in regions 2, 4 and 5 are not synthesizing DNA and have no BrdU incorporated.
- DNA contents indicate that the R2 cells have one set of chromosomal DNA and in the stage of G0/G1.
- R4 cells have double amount of DNA compared to R2, indicating that they are in G2/M phase.
- R5 cells have DNA content equivalent to S phase cells but not synthesizing DNA, indicating that they are arrested at S phase. The percentage of the cells at each of those status are shown. Note: increased number of R5 cells are seen in Wt D- cells, but not in the mutant transfected cells (DM D-).
- Figure 11 shows BrdU incorporation and DNA content in HeLa cells transfected with CDA1-DM (double mutant).
- Cells (2 x 10 5 cells per 8 cm dish) of the stable cell line 2C6D3 expressing Myc-tagged CDA1-DM were cultured for 5 days with doxycycline to keep the transgene turned off (Off) or without doxycycline to turn the transgene on (On).
- On days 4 and 5 cells were analyzed by flow cytometry for DNA content and BrdU incorporation (Figure 11 A) and expression level of myc-tagged CDA1-DM by immunoblotting using anti-myc McAb ( Figure 11 B). Blots were reprobed with anti- ⁇ tubulin McAb to show equal loading of proteins per lane ( Figure 11C).
- Figure 12 shows interacting proteins of CDA1 in HeLa Cells.
- a nucleotide sequence encoding a cell division autoantigen (CDA) said sequence having the nucleotide sequence according to Figure 1 or SEQ ID NO:1 or a fragment, functional equivalent , analogue, mutant or variant thereof.
- CDA cell division autoantigen
- nucleotide sequence which encodes a CDA polypeptide or CDA-derived polypeptide fragment, functional equivalent, analogue, mutant or variant thereof said polypeptide having a sequence according to Figure 1 or SEQ ID NO:2.
- the cell division autoantigen has been found by the applicants to be a nuclear protein that resides primarily in the nucleolus and to a lesser extent in the nucleoplasm of the cell.
- the function of the protein has been linked to cell division because of its homology to portion of the Leukaemia-associated protein SET which is also involved in cell division control.
- the CDA has been shown by the applicants that it may halt cell growth.
- fragment relates to a portion of an amino acid or nucleic acid sequence that is less than that of full length but is capable of hybridising to a full length nucleotide or amino acid sequence capable of encoding an amino acid sequence of CDA which is a portion of the full length sequence of CDA.
- the changes do not substantially change the activity of the protein.
- the change does not result in a change in the reading frame of a protein coding region and preferably encodes a protein having no change, or only a minor reduction in biological function.
- nucleic acid sequences which encode the same or functionally equivalent amino acid sequence are included within the scope of the current invention.
- Such alterations of the nucleotide sequence may include substitutions of different nucleotides resulting in the same or a functionally equivalent gene product.
- nucleic acid sequences having deletions and/or additions and which result in a functionally equivalent gene product are also included within the scope of this invention.
- the gene product may include deletions, additions or substitutions of amino acid residues within the sequence which result in changes that still produce a functionally active product.
- the nucleotide sequence of Figure 1 or SEQ ID NO:1 is preferably the full length cDNA sequence of CDA which is approximately 2.8kb long.
- the full length CDA nucleotide sequence may include a reading frame that encodes 693 amino acids, preferably from nucleotides 204 to 2284 as represented in Figure 1 or SEQ ID NO:1.
- the mRNA for CDA preferably has an open reading frame of 2079 bp, encoding the predicted polypeptide of 693 amino acids with an apparent molecular weight of 120 kilodaltons and an acidic pi of 4.26.
- the CDA nucleotide sequence may include nuclear targeting motifs and/or cdc2 kinase phosphorylation sites as indicated in Figure 2a and 2b.
- the nuclear targeting motifs aa 9-15 are encoded by nt 153-173; aa 187-203 are encoded by nt 687-737; aa 404-407 are encoded by nt 1338-1349 and aa 411-414 are encoded by nt 1359-1370.
- the cdc2 kinase phoshophorylation sites Ser20 are encoded by nt 186-188 and Thr340 is encoded by nt 1146-.
- the present invention also includes fragments of the full length DNA sequence of CDA.
- the fragments may encode parts of the CDA molecule.
- the fragments will be derived from the nucleotide sequence of the CDA and will be capable of hybridising to the nucleotide sequence of CDA as represented by Figure 1 or SEQ ID NO:!
- the invention also includes DNA molecules including full length and fragments, functional equivalents, analogues mutants, or variants of the full length that hybridise to the nucleotide sequence of CDA according to Figure 1 or SEQ ID NO:1 or a portion thereof.
- Hybridisation may be carried out using methods known in the art. For example, hybridisation using the DNA fragments as probes may be carried out in 2xSSC, 1.0% SDS at 50°C and washed using the same conditions.
- the full length DNA sequence, functional equivalents, analogues mutants, or variants of the CDA or fragments of the CDA may be synthesised using methods known in the art or generated via genomic or cDNA libraries once having a source of CDA, DNA or protein.
- the DNA may be cleaved at various restriction sites using restriction enzymes. Other methods known in the art may be used to generate the fragments.
- fragments of DNA are overlapping fragments of DNA and are designated as clones hT4 and hT6. These clones were detected and isolated from human testis cDNA lambda gt11 expression libraries.
- FIG. 3 shows an example that the auto-antibodies react with the ⁇ - galactosidase-hT4 fusion protein produced in the recombinant lambda gt11 clone ( ⁇ gt11 ht4), but not the ⁇ galactosidase itself in the lambda g11 wild type clone( ⁇ gt11 WT), while the normal human serum is not reactive to either of the proteins.
- the nucleic acid sequences of these clones show that they are overlapping clones with identical sequences at the 3' end both containing a poly (A) tail.
- the clone hT6 is 360 bp longer than hT4.
- the DNA of the CDA may be obtained from any biological source including sera, cells or tissue.
- the sera contains auto-antibodies to self proteins (autoantigens).
- the cell lines preferably have increased cell division.
- the cells may be cancer cells including HeLa cells or Hep G2 or COS cells from the African Green Monkey.
- an expression vector or cloning vector encoding a cell division auto-antigen (CDA) said vector including the nucleotide sequence according to Figure 1 or SEQ ID NO:1, or a fragment, functional equivalent, analogue, mutant or variant thereof.
- CDA cell division auto-antigen
- the DNA containing the full length or fragment, functional equivalent, analogue, mutant or variant thereof of CDA coding sequence may be inserted into an expression vector or cloning vector.
- vector-host systems known in the art may be used. Possible vectors include, but are not limited to plasmids or modified viruses, but the vector system must be compatible with the host cell used. Such vectors include, but are not limited to, bacteriophages such as lambda derivatives, or plasmids such as pBR322 or pUC plasmid derivatives.
- the insertion into a cloning vector can, for example be accomplished by ligating the DNA fragment into the cloning vector or the expression vector which has complimentary cohesive termini.
- the ends of the DNA molecules may be enzymatically modified.
- any site desired may be produced by ligating nucleotide sequences (linkers) into the DNA termini; these ligated linkers may comprise specific chemically synthesised oligonucleotides encoding restriction endonuclease restriction sequences.
- the cleaved DNA may be modified by homopolymeric tailing.
- the nucleotide sequence ligated into the expression vector may be the full length DNA according to the Figure 1 or SEQ ID NO:1 , a fragment, functional equivalent, analogue, mutant or variant thereof.
- the variant may be generated by any of the methods described above and ligated into the vector by methods available to the skilled addressee.
- the present invention also provides a host cell transformed or transfected with an expression vector or cloning vector including a nucleotide sequence according to Figure 1 or SEQ ID NO:1 or a fragment, functional equivalent, analogue, mutant or variant thereof encoding a CDA polypeptide or CDA- derived polypeptide, functional equivalent, analogue, mutant, or variant thereof.
- Recombinant molecules can be introduced into host cells via transformation, transfection, infection, electroporation, etc., so that many copies of the gene sequence are generated.
- recombinant DNA molecule Once a particular recombinant DNA molecule is identified and isolated, several methods known in the art may be used to propagate it. Once a suitable host system and growth conditions are established, recombinant expression vectors or cloning vectors can be propagated and prepared in quantity.
- Suitable host systems to express the nucleotide sequence may include, but are not limited to, mammalian cell systems infected with virus (e.g. vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (e.g. baculovirus): microorganisms such as yeast vectors, or bacteria transformed with bacteriophage DNA, plasmid DNA, or cosmid DNA.
- virus e.g. vaccinia virus, adenovirus, etc.
- insect cell systems infected with virus e.g. baculovirus
- microorganisms such as yeast vectors, or bacteria transformed with bacteriophage DNA, plasmid DNA, or cosmid DNA.
- the bacterium is E.coli, B. Subtilis or Salmonella.
- an amino acid sequence encoding a cell division auto-antigen and having the amino acid sequence according to Figure 1 or SEQ ID NO:2 or a fragment, functional equivalent, analogue, mutant or variant thereof.
- an isolated or substantially pure CDA polypeptide encoded by an amino acid sequence (SEQ ID NO:2) or nucleotide sequence (SEQ ID NO:1) or according to Figure 1 or a fragment, functional equivalent, analogue, mutant or variant thereof.
- the polypeptide may comprise 693 amino acids ( Figure 1 or SEQ ID NO:2), and has an apparent molecular weight of 120 kDa.
- Amino acid sequence analysis shows a multiple domain structure consisting of an N-terminal praline rich (Pr) domain, a basic domain homologous to a leukaemia associated protein, and a N-terminal acidic domain ( Figure 4).
- NLS nuclear localisation signal
- CDA1 may reside in the cellular nucleus.
- Two potential phosphorylation sites by p34 cdc2 kinase may be present, indicating a role for this protein in cell cycle control.
- the protein may be isolated from natural sources or biological sources including sera, cells or tissues or may be recombinantly produced.
- the polypeptide may be isolated from autoimmune sera containing auto-antibodies to self proteins including self antibodies and self antigens.
- the autoimmune sera contains autoantigens in free and unbound form, that may bind to the cognate self antigen upon contact.
- the sera is obtained from patients having discoid lupus erythematosis (DLE).
- DLE discoid lupus erythematosis
- the polypeptide may also be isolated from cells which divide rapidly such as cancer cells, preferably HeLa cells. Other cell sources include HepG2 cell lines or COS cells derived from the African Green Monkey.
- isolated and substantially pure means that the product is significantly free of other biological materials with which it is naturally associated.
- polypeptide of the present invention may be purified using standard protein or peptide purification techniques including but are not limited to electrophoresis, centrifugation, gel filtration, precipitation, dialysis, chromatography, affinity chromatography, immunoadsorbent affinity chromatography, and gel permeation high performance liquid chromatography, isoelecthc focussing, and variations and combinations thereof.
- the protein may be isolated from recombinant sources and may be generated by gene expression systems and host systems as described above.
- polypeptide is expressed standard purification processes may be used to isolate and purify the polypeptide as described above.
- the present invention further includes CDA molecules with postranslational modifications.
- CDA molecules with postranslational modifications.
- studies by the applicants have shown that the antiproliferative activity of CDA may be dependant on its phosphorylation by the kinase p34 cdc2 .
- the phosphorylation is a serine residue or a threonine residue. More preferably the phosphorylation is at Ser20 (aa 20 or S20) or Thr 340 (aa 340 or T340) according to Figure 1 or SEQ ID NO:2.
- the present invention also includes fusion proteins comprising the CDA protein or a fragment thereof and another protein.
- the fusion protein is used to immunise rabbits and mice to produce antibodies specific to the CDA. Therefore the other protein may be directed toward improving an immune response to CDA.
- the GST fusion proteins were made using an expression plasmid vector pGEX in E.coli and purified on glutathione resin column.
- the fusion proteins contain GST and CDA (aa 552-693) (GST-hT4) or GST and CDA (aa 432-693) (GST-hT6).
- the amino acid sequence and residues are according to Figure 1 or SEQ ID NO:2.
- antibodies that specifically bind CDA polypeptide or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants, and variants thereof.
- isolated or preferably purified preparations of CDA or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants, and variants thereof may be used as immunogens.
- the immunogens may be conjugated to a carrier molecule, preferably a carrier protein.
- Carrier proteins may be any commonly used in immunology including, but not limited to, bovine serum albumin (BSA), chicken albumin, keyhole limpet hemocyanin (KLH) and the like.
- the immunogen may be injected by any number of routes including subcutaneous, intravenous, intraperitoneal, intradermal, intramuscular, mucosal, or a combination of these.
- the immunogen may be injected in soluble form, aggregate form, attached to a physical carrier, or mixed with an adjuvant, using methods and materials known in the art.
- the antibodies may be purified by methods known in the art.
- the antibodies of the invention may be used to facilitate isolation and purification of the CDA polypeptide or protein. They may also be used as probes for identifying clones in expression libraries that have inserts encoding CDA polypeptide or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants, and variants thereof. Such antibodies would have use in the purification of CDA molecules during the production of recombinant CDA for example.
- antibodies are bound to chromatography resins. Passing a protein mixture through the column allows the cognate antigen to adhere. Non-target molecules are flushed through the column to leave purified CDA which is then eluted.
- antibodies can be used to purify protein by the process of immunoprecipitation.
- Antibodies can also be used to probe for CDA and closely related proteins in cDNA expressing libraries and cell extracts.
- the skilled addressee will understand that antibody fragments (such as Fab fragments) will also be useful in the context of the present invention.
- the antibodies, particularly those which are cytotoxic, may also be used in passive immunisation to prevent or attenuate rapid cell division, preferably in cancer cells.
- the present invention also includes therapeutic or prophylactic vaccines and pharmaceutical compositions comprising CDA polypeptide or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants, and variants thereof, or antibodies to these polypeptides in a pharmaceutically acceptable carrier.
- a pharmaceutically acceptable carrier for example, an immunologically effective amount of the CDA polypeptide or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants, and variants thereof may be used.
- immunologically effective amount is used herein to mean an amount sufficient to induce an immune response.
- a method of controlling cell division including subjecting cells to an effective amount of CDA or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants, or variants thereof to reduce cell division.
- the cells may be subjected to CDA or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants, or variants thereof directly or be genetically manipulated to express CDA or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants, or variants thereof in the presence of a stimulatory signal which switches CDA production on and off.
- the cells may be induced to express the de novo CDA which has not been introduced by genetic manipulation.
- Compounds such as doxycyclin may be used to selectively switch CDA expression on and off to over- or under- express the gene. Increased CDA levels may inhibit outgrowth of cell colonies and hence inhibit cell growth.
- the CDA is encoded by a full length CDA nucleotide sequence or at least, the C-terminus of CDA.
- the protein may be isolated and purified from sources described above or may be recombinantly produced, also as described above.
- the cell division may be controlled by modulating expression and/or activity of CDA or of CDA-derived polypeptides to change the amount of CDA exposed to a cell.
- modulating expression and/or activity of CDA means modifying or altering the expression and/or activity of CDA compared to unmodified levels. Modulating expression may include increasing or inducing the expression and/or activity or reducing the expression and/or activity.
- activity as used herein relates to a function of a CDA in a cell, and includes the ability CDA to bind to chaperone, or upstream or downstream effector molecules thereby activating or repressing upstream or downstream pathways which affect cell division.
- Modulation of CDA expression and/or activity in the cell may be achieved using antagonists, inhibitors, mimetics or derivatives of the CDA.
- antagonists or “inhibitor”, as used herein, refer to a molecule which, when bound to either CDA, blocks or modulates the activity of CDA.
- Antagonists and inhibitors may include proteins, nucleic acids, carbohydrates, antibodies or any other molecules including ligands which bind to CDA. Proteins may include enzymes which can break down CDA and therefore affect the level of CDA exposed on the cell.
- Other modulators of the activity and/or expression of CDA include a range of rationally-designed, synthetic inhibitors.
- Modulation of CDA expression and/or activity may be achieved by direct or indirect methods. Modulation of expression and/or activity of CDA may be achieved using direct methods known to those of skill in the art and include, but are not limited to, knockout technology, antisense technology, triple helix technology, targeted mutation, gene therapy, regulation by agents acting on transcription. Indirect methods for modulating expression and/or activity of CDA may include targeting upstream or downstream regulators such as cytokines. In another aspect of the present invention provides antagonists to CDA polypeptides.
- Antagonists may act to inhibit activity of the CDA polypeptide generally by blocking its action on the cells.
- the antagonist may also prevent phosphorylation which appears to be important in the activity of the CDA.
- Antagonists may include antibodies or small peptides directed to the CDA polypeptide or a binding site of the CDA. They may also include mutants or derivatives if CDA which may not act in the manner of CDA but be substantially the same as CDA in physical make-up. Competition experiments may help to identify suitable CDA antagonists. These tests are generally known to the skilled addressee.
- a method of preventing and treating cancer including providing an effective amount of CDA or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants, or variants thereof to a patient in need, said amount being effective to halt or slow down cell growth.
- CDA a cervical cancer cell line
- HeLa cervical cancer cell line
- Delivery of the CDA to the cancer may be facilitated by introduction of carriers directed to the cancer. This may also be achieved by creating fusion proteins of CDA protein and a cancer specific carrier to direct the CDA to the cancer cell.
- a method of detection of cell cycle activity including measuring the presence of CDA polypeptide or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants, and variants thereof.
- CDA is implicated in cell division control. Over expression of the protein may halt cell division. Accordingly, increased cell cycle activity may be measured by an increase in CDA levels. This may be measured directly by measuring the CDA using antibodies, as hereinbefore described, or it may be measured by measuring indirect parameters such as mRNA levels and identifying an increased transcription of CDA protein.
- a method of diagnosing cancer including determining a change in levels of CDA polypeptide or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants, and variants thereof in a cell.
- the change may be an increase or decrease of CDA levels or CDA derived polypeptides in the cell relative to CDA levels in non- cancerous cells or resting cells.
- Applicants have shown that CDA levels increase in rapidly dividing cancer cells compared to resting cancer cells or normal cells and hence may be used as a cancer marker.
- the change in the CDA levels may be a measure of a change in expression of CDA or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants or variants thereof or it may be measured directly as an increase in the amounts of the polypeptide present. Any direct or indirect measurement protocol may be used including the measurement of antibodies to CDA, or bending proteins which bind to CDA.
- the cells may be extracted from the patient either as tissue samples or cell cultures may be prepared from the samples.
- the change in CDA levels may be compared against normal or resting cells, or the change may be measured within the sample as a progressive measurement taken whilst the cells continue to divide.
- a method of increasing cell division including eliminating expression of CDA polypeptide or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants, and variants thereof.
- the elimination may involve the use of cytotoxic antibodies directed at CDA.
- the antibodies may be as described above.
- a commercial human testis lambda gt11 cDNA library was screened using DLE autoimmune serum. Two overlapping cDNA fragments of CDA (designated hT4 and hT6) were detected. The products of these clones were further confirmed to be immunologically reactive with the autoimmune serum. The nucleic acid sequences of these clones show that they are overlapping clones with identical sequences at the 3' end both containing a poly(A) tail. Based on sequence information from the two clones, a full length clone, hTsl-9, from a testis sub- library was identified. The full length cDNA was found to be 2.8 kb long ( Figure 1 or SEQ ID NO:1).
- the nucleotide sequence of Figure 1 shows the full length cDNA sequence of CDA which is approximately 2.8kb long.
- the full length CDA nucleotide sequence may include a reading frame that encodes 693 amino acids, preferably from nucleotides 204 to 2284 as represented in Figure 1 or SEQ ID NO:1.
- the mRNA for CDA has an open reading frame of 2079 bp, encoding predicted polypeptide of 693 amino acids with an apparent molecular weight of 120 kilodaltons and an acidic pi of 4.26.
- Northern hyridisation on mRNA of HeLa cells and human testis is shown in Figure 6.
- Example 2 Determination of molecular weight of CDA.
- GST fusion proteins were made with CDA C-terminal fragments using cDNA clones hT4 and hT6. The proteins were used to immunise rabbits and mice. All animals produced a protein which was reactive with a 120 kDa protein present in a HeLa cell extract. Using two affinity columns to purify the rabbit antibodies specific to hT4 encoded protein, probing extracts of HeLa, HepG2 and COS cells revealed a 120 kDa protein ( Figure 7). In addition, the epressed protein of the CDA1 open reading frame also showed a 120 kDa molecular weight detected by immunoblotting and immunoprecipitation which is shown in the phosphorylation experiment ( Figure 5).
- Tet-off expression system has been used to establish stable HeLa cell lines over-expressing either full-length or N-terminus CDA.
- the transgenes could be switched on or off by varying the levels of doxycyclin (Dox) in the medium.
- Dox doxycyclin
- Approximately 5000 cells were seeded in 10mm cell culture dishes and cultured with varying concentrations of Dox (5, 0.5, 0.13, 0.06, and 0 ng/mL). After culturing for two weeks, cells were fixed and stained with crystal violet. It was found that cell colony number decreases with lower Dox concentrations (ie transgene switched on) see Figure 8A. This anti-replicative effect was only noted for full-length CDA, and not for the N-terminus only.
- Trypan exclusion assays show that the cells that are arrested, the cells are dead. However, the cells with DOX are completely arrested, but over 90% of those cells were still viable meaning a majority of the cells were arrested but not dead.
- CDA contains at least two motifs that are potentially phosphorylated by p34 cdc2 kinase.
- a mutant CDA was made to have these two potential sites abolished by point mutagenesis.
- this mutant fails to show such effect on the cell growth ( Figure 10) indicating that it is essential to phosphorylate CDA, possibly by p34 cdc2 kinase, to carry out its inhibitory functions in the cell.
- phosphorylation status of CDA is critical, which is possibly regulated by cell cycle kinase, and hence dependent on the cell cycle stages.
- Example 5 BrdU incorporation and DNA content in HeLa cells transfected with CDA1-DM (double mutant).
- Cells (2 x 10 5 cells per 8 cm dish) of the stable cell line 2C6D3 expressing Myc- tagged CDA1-DM were cultured for 5 days with doxycycline to keep the transgene turned off (Off) or without doxycycline to turn the transgene on (On). On days 4 and 5, cells were analyzed by flow cytometry for DNA content and BrdU incorporation (Figure 11A) and expression level of myc-tagged CDA1-DM by immunoblotting using anti-myc McAb ( Figure11 B). Blots were reprobed with anti- ⁇ tubulin McAb to show equal loading of proteins per lane.
- Figure 11C On day 4, cells were harvested for RT-PCR to confirm presence of mutations in transcripts of expressed myc-tagged CDA1-DM transgene. Diagram shows primers for reverse transcription (P-RT) and subsequent PCR. Vector primer (P- Vect) of pTRE (5' -TTTGACCTCCATAGAAGACA- 3') and reverse CDA1 primer P3 (5' -GAGCGTGAAGTATGCGCGG- 3') were used to amplify the fragment containing S20A mutation.
- CDA1 primers, P2 5'
- CACTCTCATTGTTGTCAGTGGT- 3' were used to amplify the fragment containing the T340A mutation.
- Lamda DNA BstEU digested molecular weight markers used for 1.8% agarose gel electrophoresis.
- Hela cell total lysate was separated by SDS-PAGE (top panel: 7.5% gel; bottom panel: 12% gel) and transferred to nitrocellulose membrane.
- an overlay of purified GST fusion protein of CDA1 C-terminus (GST-CDA1-hT4) or GST protein as a control (GST) was incubated at room temperature for 1 hrs. After wash, the bound GST-CDA1 fusion protein and GST protein were detected using a rabbit anti-GST-hT4 serum.
- At least 8 HeLa proteins (indicated by arrows in Figure 12) with molecular weights of approximately 15, 30, 53, 60, 70, 90, 100 and 200 kDa were shown to specifically bind to CDA1 C-terminus, which were not shown to bind to GST control protein. Although the identities of these interacting proteins are yet to be known, this finding suggests that CDA1 interacts with multiple proteins that may be involved in a broad range of cellular regulatory pathways related to cell cycle, and perhaps cell proliferation of cancerous cells.
- Figure 12 The significance of Figure 12 is that identification of the identities of these proteins interacting with CDA1 may reveal 1). mechanisms how CDA1 acts as a cell proliferation inhibitor; 2). reveal some, perhaps novel and cancer unique, proteins/pathways that are involved in cell proliferation regulation. Drugs can be designed to mimic CDA1 actions and interactions with those proteins/pathways for use in cancer treatment
Abstract
The present invention relates to a Cell Division Autoantigen (CDA) and includes polypeptide sequences, gene sequences encoding CDA, vectors containing those sequences, and host cells transformed to contain CDA sequences. The invention also provides antibodies directed against CDA. The invention also relates to the use of CDA as a therapeutic and diagnostic agent for the treatment of cell division associated diseases including cancer. In as aspect of the present invention, there is provided a nucleotide sequences encoding a cell division autoantigen (CDA) said sequence having the nucleotide sequence according to Figure 1 or SEQ ID NO:1 or a fragment, functional equivalent, analogue, mutant or variant thereof. The invention specifically provides nucleotide and amino acid sequences including SEQ ID NO:1 and SEQ ID NO:2 respectively which encode for the CDA molecule. The invention also encompasses antisera and antibodies, including cytotoxic antibodies specific for the CDA polypeptide and/or CDA-derived polypeptides. The invention further encompasses immunogenic, prophlactic or therapeutic compositions, including vaccines, comprising one or more polypeptides. The invention additionally encompassed nucleotide sequences encoding said CDA polypeptide or CDA-derived polypeptides, functional equivalents, analogues, mutants, and variants thereof.
Description
CELL DIVISION AUTOANTIGEN (CDA) POLYPEPTIDES, GENE SEQUENCES AND USES THEREOF
The present invention relates to a Cell Division Autoantigen (CDA) and includes polypeptide sequences, gene sequences encoding CDA, vectors containing those sequences, and host cells transformed to contain CDA sequences. The invention also provides antibodies directed against CDA. The invention also relates to the use of CDA as a therapeutic and diagnostic agent for the treatment of cell division associated diseases including cancer.
INTRODUCTION Cancer is a general term given to a range of diseases, all of which are the result of the uncontrolled division of cells. There are a range of useful chemical entities available to clinicians for the treatment of cancer. Such agents include antimetabolites, DNA binding compounds, alkylating agents and hormones. These substances are usually cytotoxic and therefore also adversely affect normal cells.
An alternative approach to arresting uncontrolled cell division in a mammal is to identify naturally occurring proteins which act specifically to regulate the cell cycle. It is known that the cell cycle is a strictly regulated and complicated chain of events involving many regulatory proteins and pathways. Enormous information exchanges between those proteins and pathways act to maintain a balance between normal and uncontrolled cell growth. Identification of proteins which can act to arrest the growth of S phase cells by preventing the synthesis of the DNA necessary for cell division to occur could lead to use of the protein in cancer therapy. Polypeptides which are part of cell cycle regulatory pathways may be found in the nucleus of rapidly growing cells.
A problem faced in finding such specific proteins is that there are many other proteins present in the nucleus of eukaryotic cells, most with no regulatory function.
Accordingly, it is an aspect of the present invention to overcome or at least alleviate some of the problems of the prior art.
SUMMARY OF THE INVENTION In an aspect of the present invention, there is provided a nucleotide sequence encoding a cell division autoantigen (CDA) said sequence having the nucleotide sequence according to Figure 1 or SEQ ID NO:1 or a fragment, functional equivalent , analogue, mutant or variant thereof.
In another aspect of the present invention, there is provided a nucleotide sequence which encodes a CDA polypeptide or CDA-derived polypeptide fragment, functional equivalent, analogue, mutant or variant thereof said polypeptide having a sequence according to Figure 1 or SEQ ID NO:2.
The cell division autoantigen (CDA) has been found by the applicants to be a nuclear protein that resides primarily in the nucleolus and to a lesser extent in the nucleoplasm of the cell. The function of the protein has been linked to cell division because of its homology to portion of the Leukaemia-associated protein SET which is also involved in cell division control. The CDA has been shown by the applicants that it may halt cell growth.
In another aspect of the present invention there is provided an expression vector or cloning vector encoding a cell division auto-antigen (CDA) said vector including the nucleotide sequence according to Figure 1 or SEQ ID NO:1 , or a fragment, functional equivalent, analogue, mutant or variant thereof.
The present invention also provides a host cell transformed or transfected with an expression vector or cloning vector including a nucleotide sequence according to Figure 1 or SEQ ID NO:1 or a fragment, functional equivalent, analogue, mutant or variant thereof encoding a CDA polypeptide or CDA- derived polypeptide, functional equivalent, analogue, mutant, or variant thereof.
In another aspect of the present invention, there is provided an amino aci sequence encoding a cell division auto-antigen and having the amino acid
sequence according to Figure 1 or SEQ ID NO:2 or a fragment, functional equivalent, analogue, mutant or variant thereof.
In another aspect of the present invention, there is provided an isolated or sustantially pure CDA polypeptide encoded by an amino acid sequence or nucleotide sequence according to Figure 1 or SEQ ID NO:2 or a fragment, functional equivalent, analogue, mutant or variant thereof.
In another aspect of the present invention there is provided antibodies that specifically bind CDA polypeptide or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants, and variants thereof.
The present invention also includes therapeutic or prophylactic vaccines and pharmaceutical compositions comprising CDA polypeptide or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants, and variants thereof, or antibodies to these polypeptides in a pharmaceutically acceptable carrier. In the vaccines an immunologically effective amount of the CDA polypeptide or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants, and variants thereof may be used.
In another aspect of the present invention provides antagonists to CDA poylpeptides.
Antagonists may act to inhibit activity of the CDA polypeptide generally by blocking its action on the cells. The antagonist may also prevent phosphorylation which appears to be important in the activity of the CDA.
In yet another aspect of the present invention there is provided a method of controlling cell division, said method including subjecting cells to an effective amount of CDA or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants, and variants thereof to control cell division.
In yet another aspect of the present invention, there is provided a method of preventing and treating cancer, said method including providing an effective
amount of CDA or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants, and variants thereof to a patient in need, said amount being effective to halt or slow down cell growth.
In another aspect of the invention there is provided a method of detection of cell cycle activity, said method including measuring the presence of CDA polypeptide or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants, and variants thereof.
In another aspect of the present invention there is provided a method of increasing cell division, said method including eliminating expression of CDA polypeptide or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants, and variants thereof.
In summary, the present invention encompasses the CDA polypeptide and CDA-derived polypeptides and methods for making the peptides. The invention also encompasses antisera and antibodies, including cytotoxic antibodies specific for the CDA polypeptide and/or CDA-derived polypeptides. The invention further encompasses immunogenic, prophylactic or therapeutic compositions, including vaccines, comprising one or more polypeptides. The invention additionally encompasses nucleotide sequences encoding said CDA polypeptide or CDA-derived polypeptides, functional equivalents, analogues, mutants, and variants thereof.
DESCRIPTION OF FIGURES
Figure 1 shows the nucleotide sequence and the amino acid sequence of CDA.
Figure 2a and Figure 2b shows nucleic acid and predicted amino acid sequences of CDA. The predicted amino acids are represented by single letter codes with an in-frame stop codon (*). The sequence shows 4 putative nuclear targeting motifs (boxed), two putative cdc2 kinase phosphorylation sites (shaded) with the candidate phosphorylated residue in bold, and polyadenylation signal sequence (bold and italics) located 15 nucleotides
upstream of poly (A) tail. Amino acids in the central and C-terminal tail which are homologous to SET are underlined.
Figure 3 shows immunoblot and immunoreactivity of clone hT4 with the autoimmune serum β-galactosidase fusion protein with estimated molecular weight of 135 kDa (arrow) produced by lambda gt11 clone hT4 (λgt11 hT4), is immunoreactive with the autoimmune serum, but not with the normal human serum, β-galactosidase protein (120 kDa) produced by wild type lambda gt11 (λgt 11 WT) is not reactive with the autoimmune serum.
Figure 4 shows the molecular and structural features of CDA. I, stick diagram showing N-terminal proline rich (Pr) domain (aa 4 - 121), basic domain (aa 180 - 418), C-terminal acidic domain comprising two acidic regions (aa 420-536 and 564-675, respectively), 4 putative nuclear targeting motifs (aa 9-15; 187- 203; 404-407 and 411-414) and 2 cdc2 kinase phophorylation sites (Ser20 and Thr340). II, Kyte-Doolitle hydrophilicity profile showing that CDA1 is generally hydrophilic. Ill, predicted secondary structure showing regions forming α- helices (Helix), β-pleated sheet (Sheet) and reverse turns (Turns) using the methods of Chou-Fasman (CF) and Robson-Garnier (RG); agreed predictions between these two methods are presented for α-helices (CFRg Trn). β-Pleated sheet (CFRg Sht) and reverse turns (CFRg Trn). IV and V, profiles of acidic (A) and basic (B) amino acid residues of CDA1 and human SET respectively.
Figure 5 shows CDA is phosphorylated in vivo. Overexpressed myc-tagged full length (A) and N-terminal two thids (B) of CDA1 are metabolically labelled by 35S-methionine and immunoprecipitated by anti-myc-tag McAb 9E10, and migrate in the SDS-PAGE as apparent molecular weight of 120 kDa (arrow) and 60 kDa (arrow), respectively. They both are labelled by 32P in vivo and immuno- precipitate any 35S, nor 32P labelled proteins.
Figure 6 shows Northern blots illustrating molecular size of CDA mRNA in human testis tissue and HeLa cell lines. RNA blots show a single 2.8 kb mRNA band of CDA in HeLa cells and human testis detected by hybridisation with CDA cDNA probes labelled with 32P-dCTP. Approximately 350ng poly A+ RNA of
Hela cells and human testis were hybridised respectively with probe 1 (PCR fragment from clone hT6 corresponding to nucleotides 1421 - 2280) and probe 2 and 3 (PCR fragments from clone hTsl-9 corresponding respectively to nucleotides 1595 - 2808 and 741 - 1418).
Figure 7 shows species distribution of CDA. A: Rabbit antiserum raised against a bacterial fusion protein of GST and CDA1 C-terminus (GST-hT4) is affinity purified by firstly removing anti-GST antibodies followed by a GST-hT4 fusion protein affinity column purification. Whole serum (i) contains both anti-GST (lanes 1) and anti-GST-hT4 fusion protein (lanes 2) antibodies; the flow-through fraction of the first GST-column (ii) with anti-GST antibodies removed retains the anti-GST-hT4 fusion protein antibodies (iii) are reactive with GST-hT4 fusion protien, but not with the purified GST. B: The affinity purified antibodies are reactive with CDA1 of approimately 120 kDa in HeLa and HepG2 cells of human origin, as well as COS cells of monkey. No band around 120 kDa was detected by the antibodies from cell lines of dog (MDCK), mouse (thymus B6TEA and 133.D7), hamster (CHO and BHK) and chicken (SSC). Approximately 30 μg/lane total protein extract was loaded, and the blot was re- blotted with anti-alpha tubuline monoclonal antibody to show equal loading of each lane.
Figure 8A and 8B (1 and 2) shows the effect of various levels of CDA on cell growth. A: Approximately 5,000 cells of the stable cell lines with full length and N-terminus of CDA were mixed with untransfected HeLa cells as supporter or feeder cells and cultured with various concentrations of DOX in the medium. After 2 days hygromycin was added to kill the feeder HeLa cells. The cells were cultured in presence of hygromycin for additional 10 days with the medium changed every 4-5 days. The out-grown cell colonies were fixed in dish and stained with crystal violet before photograph. The DOX concentrations are: 5.00ng/mL (a); O.δOng.mL (b); 0.25ng/mL (c); 0.13ng/mL (d); 0.06ng.mL (e) and O.OOng/mL (f). B: Approimately 2 x 105 cells were seeded in each dish (10cm) and cultured in presence of DOX at various concentrations as indicated for 4 days. Cells were labelled with BrdU for 1 hr and stained with anti-BrdU Ab- FITC conjugate and propidium iodide. The dot plot shows the DNA
synthesizing cells content equivalent to S phase cells but are not synthesizing DNA are measured and shown (R4). The viability of the cells determined by Trypan blue eclusion assay is also shown (Viable). The histogram shows the number of cells (counts) against the DNA contents (FL2-A). B1 shows the results for full length CDA and B2 shows results for N-terminus CDA.
Figure 9A and 9B show effect of CDA overexpression on cell growth. A: Equal number of cells (4 x 104) were seeded in 6 well plates and cultured with DOX in the medium overnight. To switch the transgene on, the DOX was removed by replacing the medium and the cells were cultured for 1-5 days. Cells were fixed and stained with 0.1% crystal violet daily. The cell associated dye was then extracted in 10% acetic acid, and the OD (495nm) was measured and plotted against the days. Full length CDA cell line is represented by the faint bar, while the N-terminus cell line by the solid bar. B: Approximately 2 x 105 cells were seed in each 10mm dish, and cultured without DOX to switch on the transgene for 5 days. Cells were labelled with BrdU and harvested daily for FACS scan. The dot plot shows the DNA synthesizing cells incorporating BrdU (FL1 H) and the DNA contents (FL2-A). Percentage of the cells that have DNA content equivalent to S phase cells but are not synthesizing DNA are measured and shown (R4). The viability of the cells determined by Trypan blue exclusion assay is also shown (Viable). The histogram shows the number of cells (counts) against the DNA contents (FL2-A). B1 shows the results for full lengths CDA and B2 shows eresults for N-terminus CDA.
Figure 10 shows the inhibitory effect of CDA on cell growth is disabled by point mutations that abolish the potential cdc2 kinase phosphorylation sites. Approximately 4 x 106 tTa HeLa cells were transient transfected with 15 μg pTRE construct containing either wild type CDA (Wt) or a double mutant (DM) CDA that has 2 point mutations (S20A and T340A). The transfected cells were cultured for 48 hrs in presence (D+) or absence (D-) of DOX before FACS analysis. The dot plots show the DNA synthesizing cells incorporating BrdU (FL1 H) and the DNA contents (FL2-A). The cells in region 3 (R3) are Synthesizing DNA and have BrdU incorporated. Cells in regions 2, 4 and 5 (R2, R4 and R5) are not synthesizing DNA and have no BrdU incorporated. DNA
contents indicate that the R2 cells have one set of chromosomal DNA and in the stage of G0/G1. R4 cells have double amount of DNA compared to R2, indicating that they are in G2/M phase. R5 cells have DNA content equivalent to S phase cells but not synthesizing DNA, indicating that they are arrested at S phase. The percentage of the cells at each of those status are shown. Note: increased number of R5 cells are seen in Wt D- cells, but not in the mutant transfected cells (DM D-).
Figure 11 shows BrdU incorporation and DNA content in HeLa cells transfected with CDA1-DM (double mutant). Cells (2 x 105 cells per 8 cm dish) of the stable cell line 2C6D3 expressing Myc-tagged CDA1-DM were cultured for 5 days with doxycycline to keep the transgene turned off (Off) or without doxycycline to turn the transgene on (On). On days 4 and 5, cells were analyzed by flow cytometry for DNA content and BrdU incorporation (Figure 11 A) and expression level of myc-tagged CDA1-DM by immunoblotting using anti-myc McAb (Figure 11 B). Blots were reprobed with anti-α tubulin McAb to show equal loading of proteins per lane (Figure 11C).
Figure 12 shows interacting proteins of CDA1 in HeLa Cells.
DETAILED DESCRIPTION OF THE INVENTION
In an aspect of the present invention, there is provided a nucleotide sequence encoding a cell division autoantigen (CDA) said sequence having the nucleotide sequence according to Figure 1 or SEQ ID NO:1 or a fragment, functional equivalent , analogue, mutant or variant thereof.
In another aspect of the present invention, there is provided a nucleotide sequence which encodes a CDA polypeptide or CDA-derived polypeptide fragment, functional equivalent, analogue, mutant or variant thereof said polypeptide having a sequence according to Figure 1 or SEQ ID NO:2.
The cell division autoantigen (CDA) has been found by the applicants to be a nuclear protein that resides primarily in the nucleolus and to a lesser extent in the nucleoplasm of the cell. The function of the protein has been linked to cell
division because of its homology to portion of the Leukaemia-associated protein SET which is also involved in cell division control. The CDA has been shown by the applicants that it may halt cell growth.
The term "functional equivalent, analogue, mutant, or variant thereof as used herein means a sequence which functions in a similar way but may have deletions, additions or substitutions that do not substantially change the activity or function of the sequence.
The term "fragments" relates to a portion of an amino acid or nucleic acid sequence that is less than that of full length but is capable of hybridising to a full length nucleotide or amino acid sequence capable of encoding an amino acid sequence of CDA which is a portion of the full length sequence of CDA.
Throughout this specification the word "comprise" and variations of the word, such as "comprising" and "comprises", is not intended to exclude other additives, components, integers or steps.
Where these terms relate to protein, the changes do not substantially change the activity of the protein. Where it relates to a changed nucleic acid molecule, the change does not result in a change in the reading frame of a protein coding region and preferably encodes a protein having no change, or only a minor reduction in biological function.
Due to the degeneracy of the genetic code, other nucleic acid sequences which encode the same or functionally equivalent amino acid sequence are included within the scope of the current invention. Such alterations of the nucleotide sequence may include substitutions of different nucleotides resulting in the same or a functionally equivalent gene product. Also included within the scope of this invention are nucleic acid sequences having deletions and/or additions and which result in a functionally equivalent gene product. In addition the gene product may include deletions, additions or substitutions of amino acid residues within the sequence which result in changes that still produce a functionally active product.
The nucleotide sequence of Figure 1 or SEQ ID NO:1 is preferably the full length cDNA sequence of CDA which is approximately 2.8kb long. However, fragments, functional equivalents, analogues, mutants, or variants are also included in the scope of the invention. The full length CDA nucleotide sequence may include a reading frame that encodes 693 amino acids, preferably from nucleotides 204 to 2284 as represented in Figure 1 or SEQ ID NO:1. The mRNA for CDA preferably has an open reading frame of 2079 bp, encoding the predicted polypeptide of 693 amino acids with an apparent molecular weight of 120 kilodaltons and an acidic pi of 4.26.
The CDA nucleotide sequence may include nuclear targeting motifs and/or cdc2 kinase phosphorylation sites as indicated in Figure 2a and 2b. The nuclear targeting motifs aa 9-15 are encoded by nt 153-173; aa 187-203 are encoded by nt 687-737; aa 404-407 are encoded by nt 1338-1349 and aa 411-414 are encoded by nt 1359-1370. The cdc2 kinase phoshophorylation sites Ser20 are encoded by nt 186-188 and Thr340 is encoded by nt 1146-.
The present invention also includes fragments of the full length DNA sequence of CDA. The fragments may encode parts of the CDA molecule. The fragments will be derived from the nucleotide sequence of the CDA and will be capable of hybridising to the nucleotide sequence of CDA as represented by Figure 1 or SEQ ID NO:!
The invention also includes DNA molecules including full length and fragments, functional equivalents, analogues mutants, or variants of the full length that hybridise to the nucleotide sequence of CDA according to Figure 1 or SEQ ID NO:1 or a portion thereof. Hybridisation may be carried out using methods known in the art. For example, hybridisation using the DNA fragments as probes may be carried out in 2xSSC, 1.0% SDS at 50°C and washed using the same conditions.
The full length DNA sequence, functional equivalents, analogues mutants, or variants of the CDA or fragments of the CDA may be synthesised using
methods known in the art or generated via genomic or cDNA libraries once having a source of CDA, DNA or protein. In preparing fragments of the CDA nucleotide sequence, the DNA may be cleaved at various restriction sites using restriction enzymes. Other methods known in the art may be used to generate the fragments.
Preferably the fragments of DNA are overlapping fragments of DNA and are designated as clones hT4 and hT6. These clones were detected and isolated from human testis cDNA lambda gt11 expression libraries.
The open reading frame of hT4 and hT6 respectively enoded the C-terminal 142 and 262 amino acids of CDA hT4 starts from the nucleic acid codon for the amino acid 552 (aa552) and hT6 starts from the nucleic acid codon for the amino acid 432 (aa 432) according to Figure 1 or SEQ ID NO:1.
The products of the clones were further immunologically reactive with the autoimmune serum from the particular discoid lupus erythematosis (DLE) patients. Figure 3 shows an example that the auto-antibodies react with the β- galactosidase-hT4 fusion protein produced in the recombinant lambda gt11 clone (λgt11 ht4), but not the βgalactosidase itself in the lambda g11 wild type clone(λgt11 WT), while the normal human serum is not reactive to either of the proteins. The nucleic acid sequences of these clones show that they are overlapping clones with identical sequences at the 3' end both containing a poly (A) tail. The clone hT6 is 360 bp longer than hT4.
The DNA of the CDA may be obtained from any biological source including sera, cells or tissue. Preferably the sera contains auto-antibodies to self proteins (autoantigens). The cell lines preferably have increased cell division. The cells may be cancer cells including HeLa cells or Hep G2 or COS cells from the African Green Monkey.
In another aspect of the present invention there is provided an expression vector or cloning vector encoding a cell division auto-antigen (CDA) said vector
including the nucleotide sequence according to Figure 1 or SEQ ID NO:1, or a fragment, functional equivalent, analogue, mutant or variant thereof.
The DNA containing the full length or fragment, functional equivalent, analogue, mutant or variant thereof of CDA coding sequence may be inserted into an expression vector or cloning vector. A large number of vector-host systems known in the art may be used. Possible vectors include, but are not limited to plasmids or modified viruses, but the vector system must be compatible with the host cell used. Such vectors include, but are not limited to, bacteriophages such as lambda derivatives, or plasmids such as pBR322 or pUC plasmid derivatives. The insertion into a cloning vector can, for example be accomplished by ligating the DNA fragment into the cloning vector or the expression vector which has complimentary cohesive termini. However, if the complementary restriction sites used to fragment the DNA are not present in the vector, the ends of the DNA molecules may be enzymatically modified. Alternatively, any site desired may be produced by ligating nucleotide sequences (linkers) into the DNA termini; these ligated linkers may comprise specific chemically synthesised oligonucleotides encoding restriction endonuclease restriction sequences. In an alternative method, the cleaved DNA may be modified by homopolymeric tailing.
The nucleotide sequence ligated into the expression vector may be the full length DNA according to the Figure 1 or SEQ ID NO:1 , a fragment, functional equivalent, analogue, mutant or variant thereof. The variant may be generated by any of the methods described above and ligated into the vector by methods available to the skilled addressee.
The present invention also provides a host cell transformed or transfected with an expression vector or cloning vector including a nucleotide sequence according to Figure 1 or SEQ ID NO:1 or a fragment, functional equivalent, analogue, mutant or variant thereof encoding a CDA polypeptide or CDA- derived polypeptide, functional equivalent, analogue, mutant, or variant thereof.
Recombinant molecules can be introduced into host cells via transformation, transfection, infection, electroporation, etc., so that many copies of the gene sequence are generated.
Once a particular recombinant DNA molecule is identified and isolated, several methods known in the art may be used to propagate it. Once a suitable host system and growth conditions are established, recombinant expression vectors or cloning vectors can be propagated and prepared in quantity.
Suitable host systems to express the nucleotide sequence may include, but are not limited to, mammalian cell systems infected with virus (e.g. vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (e.g. baculovirus): microorganisms such as yeast vectors, or bacteria transformed with bacteriophage DNA, plasmid DNA, or cosmid DNA. Preferably, the bacterium is E.coli, B. Subtilis or Salmonella.
In another aspect of the present invention, there is provided an amino acid sequence encoding a cell division auto-antigen and having the amino acid sequence according to Figure 1 or SEQ ID NO:2 or a fragment, functional equivalent, analogue, mutant or variant thereof.
In another aspect of the present invention, there is provided an isolated or substantially pure CDA polypeptide encoded by an amino acid sequence (SEQ ID NO:2) or nucleotide sequence (SEQ ID NO:1) or according to Figure 1 or a fragment, functional equivalent, analogue, mutant or variant thereof.
The polypeptide may comprise 693 amino acids (Figure 1 or SEQ ID NO:2), and has an apparent molecular weight of 120 kDa. Amino acid sequence analysis shows a multiple domain structure consisting of an N-terminal praline rich (Pr) domain, a basic domain homologous to a leukaemia associated protein, and a N-terminal acidic domain (Figure 4). Four putative nuclear localisation signal (NLS) sequences are identified, indicating that CDA1 may reside in the cellular nucleus. Two potential phosphorylation sites by p34cdc2 kinase may be present, indicating a role for this protein in cell cycle control.
The protein may be isolated from natural sources or biological sources including sera, cells or tissues or may be recombinantly produced.
Where the polypeptide is from natural sources, it may be isolated from autoimmune sera containing auto-antibodies to self proteins including self antibodies and self antigens. The autoimmune sera contains autoantigens in free and unbound form, that may bind to the cognate self antigen upon contact. Preferably the sera is obtained from patients having discoid lupus erythematosis (DLE). The polypeptide may also be isolated from cells which divide rapidly such as cancer cells, preferably HeLa cells. Other cell sources include HepG2 cell lines or COS cells derived from the African Green Monkey.
As used herein the term "isolated and substantially pure" means that the product is significantly free of other biological materials with which it is naturally associated.
The polypeptide of the present invention may be purified using standard protein or peptide purification techniques including but are not limited to electrophoresis, centrifugation, gel filtration, precipitation, dialysis, chromatography, affinity chromatography, immunoadsorbent affinity chromatography, and gel permeation high performance liquid chromatography, isoelecthc focussing, and variations and combinations thereof.
The protein may be isolated from recombinant sources and may be generated by gene expression systems and host systems as described above.
Once the polypeptide is expressed standard purification processes may be used to isolate and purify the polypeptide as described above.
The present invention further includes CDA molecules with postranslational modifications. Without being limited by theory, studies by the applicants have shown that the antiproliferative activity of CDA may be dependant on its phosphorylation by the kinase p34cdc2. Studies show that point mutations in
CDA to regions containing putative phosphorylation signals lead to the abolition of activity. Therefore a particular embodiment of the present invention includes a CDA molecule which is phorphorylated at one or more amino acid residues. Preferably the phosphorylation is a serine residue or a threonine residue. More preferably the phosphorylation is at Ser20 (aa 20 or S20) or Thr 340 (aa 340 or T340) according to Figure 1 or SEQ ID NO:2.
The phosphorylation status of CDA in vivo has been examined by the applicants. Both full length and N-terminus of CDA were expressed in transfected HeLa cells and metabolically labelled with radioactive isotopes 35S and inorganic 32P followed by immunoprecipitation using anti-myc tag McAb 9E10. Both 35S labelled full length and N-terminus were specifically immunoprecipitated and showed molecular weights of approximately 120kDa and 60kDa, respectively. These are labelled with inorganic 32P (Figure 5) indicating that CDA is phosphorylated in vivo.
The present invention also includes fusion proteins comprising the CDA protein or a fragment thereof and another protein. Preferably the fusion protein is used to immunise rabbits and mice to produce antibodies specific to the CDA. Therefore the other protein may be directed toward improving an immune response to CDA.
Applicants have produced GST fusion proteins with CDA C-terminal fragments using cDNA clones hT4 and hT6. The GST fusion proteins were made using an expression plasmid vector pGEX in E.coli and purified on glutathione resin column. The fusion proteins contain GST and CDA (aa 552-693) (GST-hT4) or GST and CDA (aa 432-693) (GST-hT6). The amino acid sequence and residues are according to Figure 1 or SEQ ID NO:2.
In another aspect of the present invention there is provided antibodies that specifically bind CDA polypeptide or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants, and variants thereof.
For the production of such antibodies, isolated or preferably purified preparations of CDA or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants, and variants thereof may be used as immunogens. The immunogens may be conjugated to a carrier molecule, preferably a carrier protein. Carrier proteins may be any commonly used in immunology including, but not limited to, bovine serum albumin (BSA), chicken albumin, keyhole limpet hemocyanin (KLH) and the like.
Polyclonal and monoclonal antibodies are included in the scope of the present invention. Immunization regimes for production of both polyclonal and monoclonal antibodies are well known in the art. The immunogen may be injected by any number of routes including subcutaneous, intravenous, intraperitoneal, intradermal, intramuscular, mucosal, or a combination of these. The immunogen may be injected in soluble form, aggregate form, attached to a physical carrier, or mixed with an adjuvant, using methods and materials known in the art. The antibodies may be purified by methods known in the art.
The antibodies of the invention may be used to facilitate isolation and purification of the CDA polypeptide or protein. They may also be used as probes for identifying clones in expression libraries that have inserts encoding CDA polypeptide or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants, and variants thereof. Such antibodies would have use in the purification of CDA molecules during the production of recombinant CDA for example. In a preferred embodiment antibodies are bound to chromatography resins. Passing a protein mixture through the column allows the cognate antigen to adhere. Non-target molecules are flushed through the column to leave purified CDA which is then eluted. In another embodiment antibodies can be used to purify protein by the process of immunoprecipitation. Antibodies can also be used to probe for CDA and closely related proteins in cDNA expressing libraries and cell extracts. The skilled addressee will understand that antibody fragments (such as Fab fragments) will also be useful in the context of the present invention.
The antibodies, particularly those which are cytotoxic, may also be used in passive immunisation to prevent or attenuate rapid cell division, preferably in cancer cells.
The present invention also includes therapeutic or prophylactic vaccines and pharmaceutical compositions comprising CDA polypeptide or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants, and variants thereof, or antibodies to these polypeptides in a pharmaceutically acceptable carrier. In the vaccines an immunologically effective amount of the CDA polypeptide or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants, and variants thereof may be used.
The term "immunologically effective amount" is used herein to mean an amount sufficient to induce an immune response.
In yet another aspect of the present invention there is provided a method of controlling cell division, said method including subjecting cells to an effective amount of CDA or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants, or variants thereof to reduce cell division.
The cells may be subjected to CDA or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants, or variants thereof directly or be genetically manipulated to express CDA or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants, or variants thereof in the presence of a stimulatory signal which switches CDA production on and off. Alternatively, the cells may be induced to express the de novo CDA which has not been introduced by genetic manipulation. Compounds such as doxycyclin may be used to selectively switch CDA expression on and off to over- or under- express the gene. Increased CDA levels may inhibit outgrowth of cell colonies and hence inhibit cell growth.
Preferably for its inhibitory function in cell growth, the CDA is encoded by a full length CDA nucleotide sequence or at least, the C-terminus of CDA.
Where CDA is used directly, the protein may be isolated and purified from sources described above or may be recombinantly produced, also as described above.
The cell division may be controlled by modulating expression and/or activity of CDA or of CDA-derived polypeptides to change the amount of CDA exposed to a cell. By the term "modulating expression and/or activity of CDA" as used herein means modifying or altering the expression and/or activity of CDA compared to unmodified levels. Modulating expression may include increasing or inducing the expression and/or activity or reducing the expression and/or activity.
"Activity" as used herein relates to a function of a CDA in a cell, and includes the ability CDA to bind to chaperone, or upstream or downstream effector molecules thereby activating or repressing upstream or downstream pathways which affect cell division.
Modulation of CDA expression and/or activity in the cell may be achieved using antagonists, inhibitors, mimetics or derivatives of the CDA. The terms "antagonist" or "inhibitor", as used herein, refer to a molecule which, when bound to either CDA, blocks or modulates the activity of CDA. Antagonists and inhibitors may include proteins, nucleic acids, carbohydrates, antibodies or any other molecules including ligands which bind to CDA. Proteins may include enzymes which can break down CDA and therefore affect the level of CDA exposed on the cell. Other modulators of the activity and/or expression of CDA include a range of rationally-designed, synthetic inhibitors.
Modulation of CDA expression and/or activity may be achieved by direct or indirect methods. Modulation of expression and/or activity of CDA may be achieved using direct methods known to those of skill in the art and include, but are not limited to, knockout technology, antisense technology, triple helix technology, targeted mutation, gene therapy, regulation by agents acting on transcription. Indirect methods for modulating expression and/or activity of CDA may include targeting upstream or downstream regulators such as cytokines.
In another aspect of the present invention provides antagonists to CDA polypeptides.
Antagonists may act to inhibit activity of the CDA polypeptide generally by blocking its action on the cells. The antagonist may also prevent phosphorylation which appears to be important in the activity of the CDA.
Antagonists may include antibodies or small peptides directed to the CDA polypeptide or a binding site of the CDA. They may also include mutants or derivatives if CDA which may not act in the manner of CDA but be substantially the same as CDA in physical make-up. Competition experiments may help to identify suitable CDA antagonists. These tests are generally known to the skilled addressee.
In yet another aspect of the present invention, there is provided a method of preventing and treating cancer, said method including providing an effective amount of CDA or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants, or variants thereof to a patient in need, said amount being effective to halt or slow down cell growth.
Functional studies by the applicants show that increased levels of CDA in a cervical cancer cell line, HeLa, result in cell growth halt. This property of CDA demonstrates its potential to be exploited in cancer control and treatment. Delivery of the CDA to the cancer may be facilitated by introduction of carriers directed to the cancer. This may also be achieved by creating fusion proteins of CDA protein and a cancer specific carrier to direct the CDA to the cancer cell.
In another aspect of the invention there is provided a method of detection of cell cycle activity, said method including measuring the presence of CDA polypeptide or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants, and variants thereof.
CDA is implicated in cell division control. Over expression of the protein may halt cell division. Accordingly, increased cell cycle activity may be measured by an increase in CDA levels. This may be measured directly by measuring the CDA using antibodies, as hereinbefore described, or it may be measured by measuring indirect parameters such as mRNA levels and identifying an increased transcription of CDA protein.
In another aspect there is provided a method of diagnosing cancer, said method including determining a change in levels of CDA polypeptide or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants, and variants thereof in a cell. The change may be an increase or decrease of CDA levels or CDA derived polypeptides in the cell relative to CDA levels in non- cancerous cells or resting cells. Applicants have shown that CDA levels increase in rapidly dividing cancer cells compared to resting cancer cells or normal cells and hence may be used as a cancer marker.
The change in the CDA levels may be a measure of a change in expression of CDA or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants or variants thereof or it may be measured directly as an increase in the amounts of the polypeptide present. Any direct or indirect measurement protocol may be used including the measurement of antibodies to CDA, or bending proteins which bind to CDA.
The cells may be extracted from the patient either as tissue samples or cell cultures may be prepared from the samples. The change in CDA levels may be compared against normal or resting cells, or the change may be measured within the sample as a progressive measurement taken whilst the cells continue to divide.
In another aspect of the present invention there is provided a method of increasing cell division, said method including eliminating expression of CDA polypeptide or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants, and variants thereof.
The elimination may involve the use of cytotoxic antibodies directed at CDA. The antibodies may be as described above.
The present invention will now be more fully described with reference to the accompanying examples and figures. It should be understood, however, that the description following is illustrative only and should not be taken in any way as a restriction of the generality of the invention described.
EXAMPLES Example 1 : Identification of full-length CDA cDNA and mRNA
A commercial human testis lambda gt11 cDNA library was screened using DLE autoimmune serum. Two overlapping cDNA fragments of CDA (designated hT4 and hT6) were detected. The products of these clones were further confirmed to be immunologically reactive with the autoimmune serum. The nucleic acid sequences of these clones show that they are overlapping clones with identical sequences at the 3' end both containing a poly(A) tail. Based on sequence information from the two clones, a full length clone, hTsl-9, from a testis sub- library was identified. The full length cDNA was found to be 2.8 kb long (Figure 1 or SEQ ID NO:1).
The nucleotide sequence of Figure 1 shows the full length cDNA sequence of CDA which is approximately 2.8kb long. The full length CDA nucleotide sequence may include a reading frame that encodes 693 amino acids, preferably from nucleotides 204 to 2284 as represented in Figure 1 or SEQ ID NO:1. The mRNA for CDA has an open reading frame of 2079 bp, encoding predicted polypeptide of 693 amino acids with an apparent molecular weight of 120 kilodaltons and an acidic pi of 4.26. Northern hyridisation on mRNA of HeLa cells and human testis is shown in Figure 6.
Example 2: Determination of molecular weight of CDA.
GST fusion proteins were made with CDA C-terminal fragments using cDNA clones hT4 and hT6. The proteins were used to immunise rabbits and mice. All animals produced a protein which was reactive with a 120 kDa protein present in a HeLa cell extract. Using two affinity columns to purify the rabbit antibodies
specific to hT4 encoded protein, probing extracts of HeLa, HepG2 and COS cells revealed a 120 kDa protein (Figure 7). In addition, the epressed protein of the CDA1 open reading frame also showed a 120 kDa molecular weight detected by immunoblotting and immunoprecipitation which is shown in the phosphorylation experiment (Figure 5).
Example 3: Transfection of HeLa cells with CDA - Cell cycle effects
Tet-off expression system has been used to establish stable HeLa cell lines over-expressing either full-length or N-terminus CDA. The transgenes could be switched on or off by varying the levels of doxycyclin (Dox) in the medium. Approximately 5000 cells were seeded in 10mm cell culture dishes and cultured with varying concentrations of Dox (5, 0.5, 0.13, 0.06, and 0 ng/mL). After culturing for two weeks, cells were fixed and stained with crystal violet. It was found that cell colony number decreases with lower Dox concentrations (ie transgene switched on) see Figure 8A. This anti-replicative effect was only noted for full-length CDA, and not for the N-terminus only.
As the decreased DOX concentrations result in increased expression levels of CDA transgene, this means that increased CDA level inhibits the out-growth of the cell colonies, hence inhibits the cell growth.
Overexpression of N-terminal truncated form of CDA does not show such inhibitory effect on cell growth indicating the requirement if full length or at least the C-terminus of CDA for its inhibitory function in cell growth.
This dose dependent manner of cell growth inhibition is further investigated by FACS analysis and cell viability studies. Equal numbers of cells were seeded in each well and cultured for 5 days with selected DOX concentrations in the media. Figure 8B shows that when the full length CDA transgene is fully turned on (0.00 ng/ml DOX), all the S phase cells stop DNA synthesising, and fall from R3 to R4, indicating that those cells are arrested. The non-DNA synthesising S phase cells are minimum when the transgene is fully turned off with 5 ng/ml DOX, and increases with decreased DOX concentrations (0.25 ng/ml and 0.03
ng/ml), confirming the dose dependent manner of the effect. Again, this effect was not observed with the N-terminus truncated form of CDA.
Trypan exclusion assays show that the cells that are arrested, the cells are dead. However, the cells with DOX are completely arrested, but over 90% of those cells were still viable meaning a majority of the cells were arrested but not dead.
An experiment of time course expression of CDA shows that the inhibition of increased level of CDA on cell growth takes place 48 hours after the transgene is switched on, and the cells completely stop growing after 72 hours. Figure 9A shows that HeLa cells slow down the growth by cell number measurement 2 days after the full length CDA transgene is turned on compared to the N- terminus. After 3 days and on, the full length cells stop the cell number increasing, while the N-terminus cells are rapidly growing. This confirms the inhibitory effects of CDA on cell growth, and also indicates the requirement of full length or at least the C-terminus to function as an inhibitory protein..
Flow cytometry analysis starts to detect cell cycle arrest on day 3 (Figure 9B). The dot blot shows that S phase cells (R3) are falling down, meaning decreased BrdU incorporation rate. On days 4 and 5, the S phase cells have completely dropped out of R3, meaning that the DNA synthesis fully stops. This event is not observed with the N-terminus cells and is consistent with the findings in the cell growth assay. Trypan blue assays show again, that over 90% of those cells are still viable, meaning that they are arrested rather than dead.
In summary, increased levels of CDA results in cell arrest in all the cell cycle stages.
Example 4:Phosphorylation of CDA
CDA contains at least two motifs that are potentially phosphorylated by p34cdc2 kinase. A mutant CDA was made to have these two potential sites abolished by point mutagenesis. As wild type CDA has the ability to stop the whole cell cycle progression, this mutant fails to show such effect on the cell growth (Figure 10)
indicating that it is essential to phosphorylate CDA, possibly by p34cdc2 kinase, to carry out its inhibitory functions in the cell. In addition to the regulation of the CDA levels in various cell cycles, phosphorylation status of CDA is critical, which is possibly regulated by cell cycle kinase, and hence dependent on the cell cycle stages.
Example 5: BrdU incorporation and DNA content in HeLa cells transfected with CDA1-DM (double mutant).
Cells (2 x 105 cells per 8 cm dish) of the stable cell line 2C6D3 expressing Myc- tagged CDA1-DM were cultured for 5 days with doxycycline to keep the transgene turned off (Off) or without doxycycline to turn the transgene on (On). On days 4 and 5, cells were analyzed by flow cytometry for DNA content and BrdU incorporation (Figure 11A) and expression level of myc-tagged CDA1-DM by immunoblotting using anti-myc McAb (Figure11 B). Blots were reprobed with anti-α tubulin McAb to show equal loading of proteins per lane. (Figure 11C): On day 4, cells were harvested for RT-PCR to confirm presence of mutations in transcripts of expressed myc-tagged CDA1-DM transgene. Diagram shows primers for reverse transcription (P-RT) and subsequent PCR. Vector primer (P- Vect) of pTRE (5' -TTTGACCTCCATAGAAGACA- 3') and reverse CDA1 primer P3 (5' -GAGCGTGAAGTATGCGCGG- 3') were used to amplify the fragment containing S20A mutation. CDA1 primers, P2 (5'
CCGCTACTTGACCAATCTGC- 3') and P1 (5'
CACTCTCATTGTTGTCAGTGGT- 3') were used to amplify the fragment containing the T340A mutation. RT-PCR or PCR products derived from (1) cells with transgene turned off, (2) cells with transgene turned on, (3) wild type CDA1 plasmid and (4) mutant CDA1-DM plasmid. 1' - 4': Naή Digestion of corresponding PCR products. Lamda DNA BstEU digested molecular weight markers used for 1.8% agarose gel electrophoresis.
Example 6: Interacting Proteins of CDA1 in HeLa Cells.
Hela cell total lysate was separated by SDS-PAGE (top panel: 7.5% gel; bottom panel: 12% gel) and transferred to nitrocellulose membrane. On the blot, an overlay of purified GST fusion protein of CDA1 C-terminus (GST-CDA1-hT4) or GST protein as a control (GST) was incubated at room temperature for 1 hrs.
After wash, the bound GST-CDA1 fusion protein and GST protein were detected using a rabbit anti-GST-hT4 serum. At least 8 HeLa proteins (indicated by arrows in Figure 12) with molecular weights of approximately 15, 30, 53, 60, 70, 90, 100 and 200 kDa were shown to specifically bind to CDA1 C-terminus, which were not shown to bind to GST control protein. Although the identities of these interacting proteins are yet to be known, this finding suggests that CDA1 interacts with multiple proteins that may be involved in a broad range of cellular regulatory pathways related to cell cycle, and perhaps cell proliferation of cancerous cells.
The significance of Figure 12 is that identification of the identities of these proteins interacting with CDA1 may reveal 1). mechanisms how CDA1 acts as a cell proliferation inhibitor; 2). reveal some, perhaps novel and cancer unique, proteins/pathways that are involved in cell proliferation regulation. Drugs can be designed to mimic CDA1 actions and interactions with those proteins/pathways for use in cancer treatment
Finally it is to be understood that various other modifications and/or alterations may be made without departing from the spirit of the present invention as outlined herein.
Claims
1. A nucleotide sequence encoding a cell division autoantigen (CDA) said sequence: having the nucleotide sequence according to Figure 1 or SEQ ID NO:1 or a fragment, functional equivalent , analogue, mutant or variant thereof; or having a sequence capable of hybridizing to the nucleotide sequence of CDA according to Figure 1 or SEQ ID NO:1 or a fragment, functional equivalent, analogue, mutant or variant thereof; or having a sequence which is complementary to a sequence according to
Figure 1 or SEQ. ID NO:1 or a fragment, functional equivalent , analogue, mutant or variant thereof.
2. A nucleotide sequence which encodes a CDA polypeptide or CDA- derived polypeptide fragment, functional equivalent, analogue, mutant or variant thereof said polypeptide having a polypeptide sequence according to Figure 1 or SEQ ID NO:2. or a fragment, functional equivalent , analogue, mutant or variant thereof
3. A nucleotide sequence according to claim 1 or 2 including a reading frame encoded by nucleotides 204 to 2284 as represented in Figure 1 or SEQ ID NO:1 or a fragment, functional equivalent , analogue, mutant or variant thereof
4. A nucleotide sequence according to any one of claims 1 to 3 having nuclear targeting motifs according to Figures 2a or 2b wherein the nuclear targeting motifs are selected from aa 9-15 encoded by nt 153-173; aa 187-203 encoded by nt 687-737; aa 404-407 encoded by nt 1338-1349 and aa 411-414 encoded by nt 1359-1370.
5. A nucleotide sequence according to any one of claims 1 to 3 having cdc2 kinase phosphorylate sites according to Figures 2a and 2b wherein the cdc2 kinase phoshophorylation sites are selected from Ser20 encoded by nt 186-188 and Thr340 encoded by nt 1146-.
6. A nucleotide sequence encoding a fragment of CDA starting from the nucleic acid codon for amino acid 552(aa552) according to Figure 1 or SEQ ID NO:1 or a fragment, functional equivalent , analogue, mutant or variant thereof.
7. A nucleotide sequence encoding a fragment of CDA starting from the nucleic acid codon for amino acid 432(aa432) according to Figure 1 or SEQ ID NO:1 or a fragment, functional equivalent , analogue, mutant or variant thereof.
8. An expression vector or cloning vector encoding a CDA said vector including the nucleotide sequence according to anyone of claims 1 to 7.
9. An expression vector according to claim 8 wherein the vector is selected from the group including bacteriophages such as lambda derivatives, or plasmids such as pBR322 or pUC plasmid derivatives.
10. A host cell transformed or transfected with an expression vector or cloning vector according to claim 8 or 9.
11. A host cell according to claim 10 derived from a host system selected from the group including mammalian cell systems infected with virus; insect cell systems infected with virus; or microorganisms including yeast vectors, or bacteria transformed with bacteriophage DNA, plasmid DNA, or cosmid DNA.
12. A host cell according to claim 11 wherein the bacterium is selected from the group including E.coli, B. Subtilis or Salmonella.
13. An amino acid sequence encoding a CDA and having the amino acid sequence according to Figure 1 or SEQ ID NO:2 or a fragment, functional equivalent, analogue, mutant or variant thereof.
14. An amino acid sequence according to claim 13 wherein the sequence starts from amino acid 552.
15. An amino acid sequence according to claim 13 wherein the sequence starts from amino acid 432.
16. An isolated or substantially pure CDA polypeptide encoded by a nucleotide sequence according to anyone of claims 1 to 7.
17. An isolated or substantially pure CDA polypeptide encoded by an amino acid sequence according to anyone of claims 13 to 15.
18. A polypeptide according to claim 16 or 17 having an apparent molecular weight of approximately 120kDa.
19. A polypeptide according to anyone of claims 16 to 18 isolated from sera, cells or tissue.
20. A polypeptide according to claim 19, wherein the sera is obtained from patients having discoid lupus erythematosis (DLE).
21. A polypeptide according to claim 19 or 20 wherein the cells are rapidly dividing cells selected from the group including HeLa cells, HepG2 cell lines or
COS cells derived from the African Green Monkey.
22. A polypeptide according to anyone of claims 16 to 21 which is phosphorylated.
23. A polypeptide according to claim 22 wherein a serine residue or a threonine residue is phosphorylated.
24. A polypeptide according to claim 23 wherein Ser20 (aa 20 or S20) or Thr 340 (aa 340 or T340) according to Figure 1 or SEQ ID NO:2 is phosphorylated.
25. An antibody that specifically binds CDA polypeptide or CDA-derived polypeptides, fragments, functional equivalents, analogues, mutants, and variants thereof, wherein said polypeptide is according to any one of claims 16 to 24.
26. A vaccine comprising a CDA polypeptide according to any one of claims 16 to 24.
27. A method of controlling cell division, said method including subjecting cells to an effective amount of a CDA or CDA-derived polypeptide, fragment, functional equivalent, analogue, mutant, or variant thereof.
28. A method according to claim 27 wherein the CDA is according to any one of claims 16 to 24.
29. A method according to claim 27 for reducing cell division, said method comprising inducing expression and/or activity of CDA or a CDA-derived polypeptide, fragment, functional equivalent, analogue, mutant, or variant thereof.
30. A method of controlling cell division, said method including subjecting cells to an effective amount of an antagonist of CDA or CDA-derived polypeptide, fragment, functional equivalent, analogue, mutant, or variant thereof.
31. A method according to claim 30 wherein the antagonist is an antibody or peptide directed to the CDA polypeptide or binding site of the CDA.
32. A method according to claim 30 or 31 wherein the antagonist prevents phosphorylation of the CDA.
33. A method according to claim 30 for increasing cell division, said method including reducing expression and/or activity of a CDA polypeptide or CDA- derived polypeptide, fragment, functional equivalent, analogue, mutant, or variant thereof.
34. A method according to claim 33 wherein the CDA is according to anyone of claims 16 to 24.
35. A method of preventing and treating cancer, said method including providing an effective amount of a CDA or CDA-derived polypeptide, fragment, functional equivalent, analogue, mutant, or variant thereof to a patient in need, said effective amount being effective to halt or slow down cell growth.
36. A method according to claim 35 wherein the CDA is according to anyone of claims 16 to 24.
37. A method according to claim 35 or 36 wherein the CDA is provided by inducing expression and/or activity of a CDA or CDA-derived polypeptide, fragment, functional equivalent, analogue, mutant, or variant thereof in a cell.
38. A method of detection of cell cycle activity, said method including measuring the presence of a CDA polypeptide or CDA-derived polypeptide, fragment, functional equivalent, analogue, mutant, or variant thereof.
39. A method according to claim 38 wherein the CDA is according to anyone of claims 16 to 24.
40. A method according to claim 38 or 39 wherein the detection of cell cycle activity is a measure of expression of CDA or a CDA-derived polypeptide, fragment, functional equivalent, analogue, mutant, or variant thereof.
41. A method of diagnosis of cancer, said method comprising determining a change in levels of CDA polypeptide or CDA-derived polypeptide, fragment, functional equivalent, analogue, mutant, or variant thereof in a cell.
42. A method according to claim 41 wherein the change is a measure of expression of CDA or a CDA-derived polypeptide, fragment, functional equivalent, analogue, mutant, or variant thereof.
43. A method according to claim 42 wherein the expression is measured by a change in transcription of the CDA polypeptide.
44. A method according to claim 41 wherein the change is measured by antibodies to CDA or CDA-derived polypeptide, fragment, functional equivalent, analogue, mutant, or variant thereof.
45. A method according to claim 41 wherein an increase in CDA levels is an indication of cancer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002223261A AU2002223261A1 (en) | 2000-11-03 | 2001-11-02 | Cell division autoantigen (cda) polypeptides, gene sequences and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPR1213 | 2000-11-03 | ||
AUPR1213A AUPR121300A0 (en) | 2000-11-03 | 2000-11-03 | Cell division autoantigen (CDA) polypeptides, gene sequences and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002036768A1 true WO2002036768A1 (en) | 2002-05-10 |
Family
ID=3825256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU2001/001418 WO2002036768A1 (en) | 2000-11-03 | 2001-11-02 | Cell division autoantigen (cda) polypeptides, gene sequences and uses thereof |
Country Status (2)
Country | Link |
---|---|
AU (2) | AUPR121300A0 (en) |
WO (1) | WO2002036768A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1660114A1 (en) * | 2003-07-01 | 2006-05-31 | Dia-B Tech Limited | Methods and compositions for treating disorders of the extracellular matrix |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1033401A2 (en) * | 1999-02-26 | 2000-09-06 | Genset | Expressed sequence tags and encoded human proteins |
EP1085024A1 (en) * | 1998-06-05 | 2001-03-21 | Helix Research Institute | Peptides having nuclear transport activity |
WO2001053312A1 (en) * | 1999-12-23 | 2001-07-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
-
2000
- 2000-11-03 AU AUPR1213A patent/AUPR121300A0/en not_active Abandoned
-
2001
- 2001-11-02 AU AU2002223261A patent/AU2002223261A1/en not_active Abandoned
- 2001-11-02 WO PCT/AU2001/001418 patent/WO2002036768A1/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1085024A1 (en) * | 1998-06-05 | 2001-03-21 | Helix Research Institute | Peptides having nuclear transport activity |
EP1033401A2 (en) * | 1999-02-26 | 2000-09-06 | Genset | Expressed sequence tags and encoded human proteins |
WO2001053312A1 (en) * | 1999-12-23 | 2001-07-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
Non-Patent Citations (7)
Title |
---|
CHAI, Z. ET AL.: "SET-related cell division autoantigen-1 (CDA-1) arrests cell growth", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 36, September 2001 (2001-09-01), pages 33665 - 33674 * |
DATABASE GENBANK [online] 31 May 2000 (2000-05-31), EICHMULLER, S. ET AL., accession no. EMBL Database accession no. (AF273046) * |
DATABASE GENBANK [online] 8 June 1998 (1998-06-08), UEKI, N., accession no. EMBL Database accession no. (AB015345) * |
DATABASE PROTEIN [online] 21 December 2000 (2000-12-21), STRAUSBER, R., Database accession no. AAH01566 * |
DATABASE PROTEIN [online] 8 June 1998 (1998-06-08), UEKI, N., Database accession no. (BAA34802) * |
OZBUN, L.L. ET AL.: "Identification of differentially expressed nucleolar TGF-beta1 target (DENTT) in human lung cancer cells that is a new member of the TSPY/SET/NAP-1 superfamily", GENOMICS, vol. 73, April 2001 (2001-04-01), pages 179 - 193 * |
UEKI, N.: "Selection system for genes encoding nuclear-targeted proteins", NATURE BIOTECHNOLOGY, vol. 16, 1998, pages 1338 - 1342 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1660114A1 (en) * | 2003-07-01 | 2006-05-31 | Dia-B Tech Limited | Methods and compositions for treating disorders of the extracellular matrix |
EP1660114A4 (en) * | 2003-07-01 | 2008-06-25 | Dia B Tech Ltd | Methods and compositions for treating disorders of the extracellular matrix |
Also Published As
Publication number | Publication date |
---|---|
AU2002223261A1 (en) | 2002-05-15 |
AUPR121300A0 (en) | 2000-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PACKHAM et al. | Mammalian cells express two differently localized Bag-1 isoforms generated by alternative translation initiation | |
Flynn et al. | Identification and sequence analysis of cDNAs encoding a 110-kilodalton actin filament-associated pp60 src substrate | |
O'Connell et al. | Cloning of cDNAs encoding mammalian double-stranded RNA-specific adenosine deaminase | |
CA2848368C (en) | Compositions and methods for brown fat induction and activity using fndc5 | |
JP2012100663A (en) | Anti-inflammatory compounds and uses thereof | |
US7982002B2 (en) | Nucleic acid encoding proteins involved in protein degradation, products and methods related thereto | |
JPH10179175A (en) | New m protein | |
TW515802B (en) | Isolated sr-p70, isolated nucleic acid sequence coding therefore, nucleotide probe or primer hybridizing thereto, and the uses thereof | |
US7049395B2 (en) | Anti-inflammatory compounds and uses thereof | |
US5905146A (en) | DNA binding protein S1-3 | |
WO2002036768A1 (en) | Cell division autoantigen (cda) polypeptides, gene sequences and uses thereof | |
WO2003074559A1 (en) | Falp proteins | |
CA2402855A1 (en) | Transcription transactivator protein | |
CA2217633C (en) | Genes encoding lymphocyte interferon regulatory factor (lsirf) polypeptides | |
WO1999053057A1 (en) | Protein and gene participating in the differentiation of immortalized cells | |
JP2000135090A (en) | HUMAN H37 PROTEIN, AND cDAN CODING FOR THE SAME | |
JPH11507825A (en) | Protein having DNase activity | |
WO2001018037A2 (en) | A p53-induced protein with a death domain that can promote apoptosis | |
CA2227508A1 (en) | Paip, a novel human protein which bridges the 3' and 5' end of mrna, and use thereof as a target for translational modulation to treat human disease | |
JPH10512145A (en) | Human geranylgeranyl pyrophosphate synthetase | |
US20050239093A1 (en) | Toll-like receptor | |
US20030166058A1 (en) | 52020, a novel human melanoma associated antigen and uses therefor | |
US5945321A (en) | Ubiquitin conjugating enzymes 7, 8 and 9 | |
WO2003018776A2 (en) | IDENTIFICATION OF THE IκBNS PROTEIN AND ITS PRODUCTS | |
WO2001042286A2 (en) | Human leucine rich repeat-containing polypeptide and uses therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |